Compare JBI & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBI | BBOT |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.0M | 1.1B |
| IPO Year | N/A | N/A |
| Metric | JBI | BBOT |
|---|---|---|
| Price | $7.02 | $12.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $10.17 | ★ $23.83 |
| AVG Volume (30 Days) | ★ 1.2M | 348.8K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $888,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.58 | N/A |
| P/E Ratio | $20.95 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.73 | $8.50 |
| 52 Week High | $10.80 | $14.87 |
| Indicator | JBI | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | N/A |
| Support Level | $6.85 | N/A |
| Resistance Level | $7.28 | N/A |
| Average True Range (ATR) | 0.25 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 59.52 | 0.00 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.